Gaush Meditech

Gaush Meditech FCF Yield

The Free Cash Flow Yield of Gaush Meditech (2407.HK) as of Nov 2, 2026 is 11.93 %. In the previous year, Free Cash Flow Yield was 2.46 % — a change of 386.04% (higher).

FCF Yield

11.93 %

YoY

386.04%

Last updated:

Free Cash Flow Yield of Gaush Meditech is 2025 11.93 % . Free Cash Flow Yield of Gaush Meditech was 2024 2.46 % . It decreases by 386.04% higher compared to the previous year.

The Gaush Meditech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
15.43 CNY
Jan 1, 2020
11.85 CNY
Jan 1, 2021
12.61 CNY
Jan 1, 2022
20.14 CNY
Jan 1, 2023
18.80 CNY
Jan 1, 2024
2.46 CNY
Jan 1, 2025
11.93 CNY
The Gaush Meditech FCF Yield history
YEARFCF YieldYoY
11.93 %+386.04%
2.46 %-86.94%
18.80 %-6.64%
20.14 %+59.72%
12.61 %+6.44%
11.85 %-23.24%
15.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gaush Meditech Stock analysis

What does Gaush Meditech do? Gaush Meditech Ltd. generates revenue through four business segments. The Proprietary Products segment develops and sells surgical equipment, intraocular lenses, and diagnostic and treatment devices for ophthalmic diseases, along with related software and consumables. The Distribution segment distributes branded ophthalmic medical devices and consumables. The Technical Services segment offers after-sales services including warranty, maintenance, and consumables support. The Others segment handles equipment leasing and intellectual property agency services. Products are used in treating conditions like cataracts, glaucoma, and pediatric ophthalmology across various medical specialties. The company's primary customers include hospitals, clinics, and medical institutions specializing in ophthalmology. These institutions purchase proprietary devices, branded consumables, and technical support services. The firm's focus on ophthalmic subspecialties ensures consistent demand for its products and services in the treatment of eye diseases. Revenue streams are diversified across product development, distribution, and post-sale services. The proprietary segment drives innovation with surgical equipment and lenses, while distribution and technical services provide steady income from established medical partners. Equipment leasing and IP services in the Others segment contribute to additional revenue without requiring direct product sales. Gaush Meditech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gaush Meditech stock

Free Cash Flow Yield of Gaush Meditech is 11.93 % in 2025.

Free Cash Flow Yield of Gaush Meditech changed from 2.46 % to 11.93 %, representing a 386.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Gaush Meditech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Gaush Meditech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Gaush Meditech

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Gaush Meditech